ARTICLE | Clinical News
BAX 817: Phase III data
March 23, 2015 7:00 AM UTC
An open-label, international Phase III trial in about 40 male patients ages 12-65 with hemophilia A or B with inhibitors showed that on-demand treatment with 3 IV injections of 90 ug/kg BAX 817 and 1 ...